{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T14:07:42Z","timestamp":1771250862101,"version":"3.50.1"},"reference-count":24,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:00:00Z","timestamp":1771027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Reports"],"abstract":"<jats:p>As survival rates for children with cancer and immune disorders have improved, clinical focus has shifted toward managing serious treatment-related complications. Intestinal perforation remains life-threatening and is typically diagnosed by signs of peritonitis and inflammation. This report presents three high-risk pediatric patients who developed severe intestinal perforation without the usual clinical symptoms. Each patient was receiving high-dose corticosteroids and\/or targeted biologic immunomodulators (ruxolitinib, anakinra, tocilizumab, eculizumab). Classic indicators such as fever, leukocytosis, hemodynamic instability, and abdominal pain were absent, despite surgical findings of fecal contamination and bowel necrosis. All three patients survived to hospital discharge. These cases demonstrate that potent immunomodulatory therapies can mask the physiological response to perforation. Relying solely on traditional clinical signs may delay diagnosis. In this population, subtle findings such as persistent gastrointestinal bleeding, feeding intolerance, or minor imaging abnormalities should prompt consideration of perforation. Early imaging and multidisciplinary review are essential for timely intervention and improved outcomes.<\/jats:p>","DOI":"10.3390\/pediatric18010030","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T12:37:28Z","timestamp":1771245448000},"page":"30","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Critical Intestinal Perforations in Pediatric Immunocompromised Patients: A Case-Based Review"],"prefix":"10.3390","volume":"18","author":[{"given":"William Hunt","family":"Stafford","sequence":"first","affiliation":[{"name":"Division of Pediatric Critical Care, University of Tennessee Health Science Center, Memphis, TN 38103, USA"},{"name":"Critical Care Medicine Division, St. Jude Children\u2019s Research Hospital, Memphis, TN 38105, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"McArthur","sequence":"additional","affiliation":[{"name":"Critical Care Medicine Division, St. Jude Children\u2019s Research Hospital, Memphis, TN 38105, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saad","family":"Ghafoor","sequence":"additional","affiliation":[{"name":"Critical Care Medicine Division, St. Jude Children\u2019s Research Hospital, Memphis, TN 38105, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,14]]},"reference":[{"key":"ref_1","unstructured":"National Cancer Institute (2025, October 01). Childhood Cancers: Child and Adolescent Cancer Fact Sheet, Available online: https:\/\/www.cancer.gov\/types\/childhood-cancers\/child-adolescent-cancers-fact-sheet."},{"key":"ref_2","first-page":"156","article-title":"Advances in paediatric cancer treatment","volume":"3","author":"Saletta","year":"2014","journal-title":"Transl. Pediatr."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Sultan, I., Alfaar, A.S., Sultan, Y., Salman, Z., and Qaddoumi, I. (2025). Trends in childhood cancer: Incidence and survival analysis over 45 years of SEER data. PLoS ONE, 20.","DOI":"10.1371\/journal.pone.0314592"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Yan, J., Duan, Y., Liu, T., Guo, J., Peng, C., Pang, W., Zhang, D., Peng, Y., and Chen, Y. (2021). Clinical features and outcomes of bowel perforation in primary pediatric gastrointestinal lymphoma. BMC Pediatr., 21.","DOI":"10.1186\/s12887-021-02944-1"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Nematolahi, S., Amanati, A., Vardanjani, H.M., Pourali, M., Bensenjan, M.H., Nozari, F., Vali, M., Mehrian, S.R.A., Nabavizadeh, S.A., and Safari, F. (2025). Investigating neutropenic enterocolitis: A systematic review of case reports and clinical insights. BMC Gastroenterol., 25.","DOI":"10.1186\/s12876-025-03601-y"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e30899","DOI":"10.1002\/pbc.30899","article-title":"Outcomes for pediatric acute lymphoblastic leukemia patients with intestinal perforation","volume":"71","author":"Canedo","year":"2024","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"20160017","DOI":"10.1259\/bjrcr.20160017","article-title":"Pneumatosis intestinalis in oncologic patients: When should the radiologist not be afraid?","volume":"3","author":"Sassi","year":"2017","journal-title":"BJR|Case Rep."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"449","DOI":"10.3348\/kjr.2008.9.5.449","article-title":"Gastrointestinal complications following hematopoietic stem cell transplantation in children","volume":"9","author":"Lee","year":"2008","journal-title":"Korean J. Radiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1038\/s41409-021-01283-0","article-title":"Transplant-associated thrombotic microangiopathy: Theoretical considerations and a practical approach to an unrefined diagnosis","volume":"56","author":"Young","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/ueg2.12736","article-title":"Gastrointestinal Perforations Associated With JAK Inhibitors: A Disproportionality Analysis of the FDA Adverse Event Reporting System","volume":"13","author":"Goldman","year":"2025","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jcrc.2021.10.020","article-title":"COVID 19 and the risk of gastro-intestinal perforation: A case series and literature review","volume":"67","author":"Bulte","year":"2022","journal-title":"J. Crit. Care"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13256-024-04905-5","article-title":"Management of chimeric antigen receptor T-cell-related toxicity of a patient affected by cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, followed by an intestinal perforation: A case report","volume":"19","author":"Menardi","year":"2025","journal-title":"J. Med. Case Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s00280-009-1062-1","article-title":"Intestinal perforation associated with rituximab therapy for post-transplant lymphoproliferative disorder after liver transplantation","volume":"64","author":"Cornejo","year":"2009","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000506514","article-title":"Hemophagocytic Lymphohistiocytosis and Inflammatory Bowel Disease: Case Report and Systematic Review","volume":"5","author":"Brambilla","year":"2020","journal-title":"Inflamm. Intest. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"rjy096","DOI":"10.1093\/jscr\/rjy096","article-title":"Hemophagocytic lymphohistiocytosis associated with Epstein\u2013Barr virus infection: Case report and literature review","volume":"2019","author":"Bahabri","year":"2019","journal-title":"J. Surg. Case Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.mce.2010.04.005","article-title":"Chapman, The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights","volume":"335","author":"Coutinho","year":"2011","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s40744-016-0037-z","article-title":"Incidence of Gastrointestinal Perforations in Patients with Rheumatoid Arthritis Treated with Tocilizumab 334 from Clinical Trial, Postmarketing, and Real-World Data Sources","volume":"3","author":"Monemi","year":"2016","journal-title":"Rheumatol. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1182\/blood-2014-09-600411","article-title":"Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS","volume":"125","author":"Cofiell","year":"2015","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s40264-018-0639-1","article-title":"Curtis, Gastrointestinal Perforations with Biologics in Patients with Rheumatoid Arthritis: Implications for Clinicians","volume":"41","author":"Jagpal","year":"2018","journal-title":"Drug Saf."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/ncprheum0338","article-title":"Interleukin 6: From bench to bedside","volume":"2","author":"Nishimoto","year":"2006","journal-title":"Nat. Clin. Pract. Rheumatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0163-7258(02)00297-8","article-title":"Mechanisms involved in the side effects of glucocorticoids","volume":"96","author":"Asadullah","year":"2002","journal-title":"Pharmacol. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/ajh.24976","article-title":"Ruxolitinib-associated infections: A systematic review and meta-analysis","volume":"93","author":"Lussana","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"337","DOI":"10.4049\/jimmunol.1600280","article-title":"Structural Basis for Eculizumab-Mediated Inhibition of the Complement Terminal Pathway","volume":"197","author":"Zhang","year":"2016","journal-title":"J. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nrd3800","article-title":"Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases","volume":"11","author":"Dinarello","year":"2012","journal-title":"Nat. Rev. Drug Discov."}],"container-title":["Pediatric Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2036-7503\/18\/1\/30\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T13:10:31Z","timestamp":1771247431000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2036-7503\/18\/1\/30"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,14]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["pediatric18010030"],"URL":"https:\/\/doi.org\/10.3390\/pediatric18010030","relation":{},"ISSN":["2036-7503"],"issn-type":[{"value":"2036-7503","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,14]]}}}